AstraZeneca (AZ; NASDAQ: AZN), a UK-based pharmaceutical giant, has presented interim results from a late-stage study combining the PARP inhibitor Lynparza (olaparib) with the anti-PD-L1 Imfinzi (durvalumab) for the treatment of newly diagnosed advanced or recurrent endometrial cancer. The study has shown promising outcomes, with the combination therapy extending the objective response rate (ORR) to 71.4% and the duration of response (DoR) to a median value not yet reached, significantly improving from the control group’s figures of 40.5% and 10.5 months, respectively.
The treatment’s efficacy was particularly noteworthy in the mismatch repair proficient (pMMR) subset of patients. In this group, the DoR doubled to 18.7 months from the control group’s 7.6 months, while the risk of second progression or death (PFS2) saw a 32% reduction.
AstraZeneca has indicated that the data from this study are currently under regulatory review worldwide, potentially paving the way for a new standard of care in the treatment of endometrial cancer.- Flcube.com
